TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform..
Read More…
Industry, Sector and Symbol
Industry Medical Instruments & Supplies
Sub-IndustryN/A
SectorMedical
Phone+1-919-7658400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
TransEnterix (NYSEAMERICAN:TRXC) Frequently Asked Questions
What is TransEnterix's stock symbol?
TransEnterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were TransEnterix's earnings last quarter?
TransEnterix, Inc. (NYSEAMERICAN:TRXC) announced its earnings results on Wednesday, August, 7th. The medical instruments supplier reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.01. The medical instruments supplier had revenue of $3.64 million for the quarter, compared to analyst estimates of $5.13 million. View TransEnterix's Earnings History.
When is TransEnterix's next earnings date?
What price target have analysts set for TRXC?
4 Wall Street analysts have issued 1-year target prices for TransEnterix's stock. Their forecasts range from $1.00 to $5.00. On average, they expect TransEnterix's stock price to reach $2.65 in the next twelve months. This suggests a possible upside of 172.3% from the stock's current price. View Analyst Price Targets for TransEnterix.
What is the consensus analysts' recommendation for TransEnterix?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TransEnterix in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TransEnterix.
Has TransEnterix been receiving favorable news coverage?
Media coverage about TRXC stock has trended positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TransEnterix earned a coverage optimism score of 2.5 on InfoTrie's scale. They also assigned news articles about the medical instruments supplier a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near future. View News Stories for TransEnterix.
Who are some of TransEnterix's key competitors?
Some companies that are related to TransEnterix include Advanced Medical Solutions Group (AMS), Clover (CLV), CRH Medical (CRH), CRH Medical (CRHM), CRH Medical (CRHM), Bovie Medical (BVX), Bovie Medical (BVX), Tristel (TSTL), InfuSystem (INFU), SDI (SDI), Impression Healthcare (IHL), G Medical (GMV), TSO3 (TOS), Daxor (DXR) and Milestone Scientific (MLSS).
What other stocks do shareholders of TransEnterix own?
Who are TransEnterix's key executives?
TransEnterix's management team includes the folowing people:
- Mr. Todd M. Pope, CEO, Pres & Director (Age 53)
- Mr. Joseph P. Slattery, Exec. VP, CFO & Principal Accounting Officer (Age 53)
- Mr. Anthony Fernando, COO, CTO & Exec. VP (Age 46)
- Mr. Joshua B. Weingard, Chief Legal Officer & Sec. (Age 45)
- Dr. Stephanie M. Fitts Ph.D., VP of RA/QA, Clinical and Compliance (Age 52)
Who are TransEnterix's major shareholders?
TransEnterix's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.15%), Vanguard Group Inc. (4.24%), Royal Bank of Canada (1.10%), Northern Trust Corp (0.92%), JPMorgan Chase & Co. (0.85%) and Nuveen Asset Management LLC (0.72%). Company insiders that own TransEnterix stock include Anthony C J Fernando, Joseph P Slattery, Todd Pope and William N Starling Jr. View Institutional Ownership Trends for TransEnterix.
Which institutional investors are selling TransEnterix stock?
TRXC stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Royal Bank of Canada, Cambridge Investment Research Advisors Inc., Northern Trust Corp, Invesco Ltd., Wells Fargo & Company MN, BNP Paribas Arbitrage SA and WINTON GROUP Ltd. Company insiders that have sold TransEnterix company stock in the last year include Joseph P Slattery and William N Starling Jr. View Insider Buying and Selling for TransEnterix.
Which institutional investors are buying TransEnterix stock?
TRXC stock was purchased by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Vanguard Group Inc., Alps Advisors Inc., First Trust Advisors LP, SG Americas Securities LLC, Migdal Insurance & Financial Holdings Ltd. and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. View Insider Buying and Selling for TransEnterix.
How do I buy shares of TransEnterix?
Shares of TRXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TransEnterix's stock price today?
One share of TRXC stock can currently be purchased for approximately $0.9731.
How big of a company is TransEnterix?
What is TransEnterix's official website?
How can I contact TransEnterix?
TransEnterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for TransEnterix (NYSEAMERICAN TRXC)
MarketBeat's community ratings are surveys of what our community members think about TransEnterix and other stocks. Vote "Outperform" if you believe TRXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRXC will underperform the S&P 500 over the long term. You may vote once every thirty days.
